Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Vidutolimod + Cemiplimab for Advanced Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is studying CMP-001 given by injection into the tumor in combination with an intravenous PD-1-blocking antibody to see how well it works in treating patients with certain types of advanced or metastatic cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.